Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?

Greene MH, Mai PL, Schwartz PE.

Am J Obstet Gynecol. 2011 Jan;204(1):19.e1-6. doi: 10.1016/j.ajog.2010.05.038. Epub 2010 Jul 8.

2.

[Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].

Arai M, Iwase T, Takazawa Y, Takeshima N.

Gan To Kagaku Ryoho. 2014 Nov;41(11):1333-9. Review. Japanese.

PMID:
25434434
3.

Risk-reducing surgery on the uterine adnexa: timing and type of surgical treatment, and pathology report.

Signorelli M, Bogani G, Ditto A, Martinelli F, Chiappa V, Lopez C, Scaffa C, Lorusso D, Raspagliesi F.

Minerva Ginecol. 2016 Oct;68(5):536-43. Epub 2016 Feb 4. Review.

PMID:
26844708
4.

Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers.

Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, Muzii L, Tombolini V, Panici PB.

BMC Womens Health. 2014 Dec 12;14:150. doi: 10.1186/s12905-014-0150-5. Review.

5.

A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer.

Michelsen TM, Dørum A, Dahl AA.

Gynecol Oncol. 2009 Apr;113(1):128-33. doi: 10.1016/j.ygyno.2008.12.024. Epub 2009 Jan 29. Review.

PMID:
19178933
6.

Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.

Kauff ND, Barakat RR.

J Clin Oncol. 2007 Jul 10;25(20):2921-7. Review.

PMID:
17617523
7.

Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer.

Berek JS, Chalas E, Edelson M, Moore DH, Burke WM, Cliby WA, Berchuck A; Society of Gynecologic Oncologists Clinical Practice Committee..

Obstet Gynecol. 2010 Sep;116(3):733-43. doi: 10.1097/AOG.0b013e3181ec5fc1. Review.

PMID:
20733460
8.

Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers.

Domchek SM, Stopfer JE, Rebbeck TR.

J Natl Compr Canc Netw. 2006 Feb;4(2):177-82. Review.

PMID:
16451773
9.

Prophylactic salpingectomy and prophylactic salpingoophorectomy for adnexal high-grade serous epithelial carcinoma: A reappraisal.

Oliver Perez MR, Magriñá J, García AT, Jiménez Lopez JS.

Surg Oncol. 2015 Dec;24(4):335-44. doi: 10.1016/j.suronc.2015.09.008. Epub 2015 Oct 8. Review.

PMID:
26690823
10.

The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.

Blok F, Roes EM, van Leenders GJ, van Beekhuizen HJ.

BMC Cancer. 2016 Jan 14;16:18. doi: 10.1186/s12885-015-2011-5. Review.

11.

Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.

Gadducci A, Biglia N, Cosio S, Sismondi P, Genazzani AR.

Gynecol Endocrinol. 2010 Aug;26(8):568-77. doi: 10.3109/09513590.2010.487609. Review.

PMID:
20632911
12.

Prophylactic oophorectomy in women at increased cancer risk.

Domchek SM, Rebbeck TR.

Curr Opin Obstet Gynecol. 2007 Feb;19(1):27-30. Review.

PMID:
17218848
13.

Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review.

Finch A, Narod SA.

Maturitas. 2011 Nov;70(3):261-5. doi: 10.1016/j.maturitas.2011.08.001. Epub 2011 Sep 4. Review.

PMID:
21893388
14.

Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations.

Olopade OI, Artioli G.

Breast J. 2004 Jan-Feb;10 Suppl 1:S5-9. Review.

PMID:
14984481
15.

Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.

Patrono MG, Iniesta MD, Malpica A, Lu KH, Fernandez RO, Salvo G, Ramirez PT.

Gynecol Oncol. 2015 Dec;139(3):568-72. doi: 10.1016/j.ygyno.2015.09.018. Epub 2015 Sep 25. Review.

PMID:
26407480
16.

Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention.

Søgaard M, Kjaer SK, Gayther S.

Acta Obstet Gynecol Scand. 2006;85(1):93-105. Review.

PMID:
16521688
17.

[Prophylactic salpingectomy or salpingo-oophorectomy as an ovarian cancer prevention?].

Chene G, Lamblin G, Le Bail-Carval K, Chabert P, Golfier F, Dauplat J, Deligdisch L, Penault-Llorca F, Mellier G.

Presse Med. 2015 Mar;44(3):317-23. doi: 10.1016/j.lpm.2014.07.024. Epub 2015 Jan 8. Review. French.

PMID:
25578546
18.

Salpingectomy as a means to reduce ovarian cancer risk.

Daly MB, Dresher CW, Yates MS, Jeter JM, Karlan BY, Alberts DS, Lu KH.

Cancer Prev Res (Phila). 2015 May;8(5):342-8. doi: 10.1158/1940-6207.CAPR-14-0293. Epub 2015 Jan 13. Review.

19.

Dealing with premature menopause in women at high-risk for hereditary genital and breast cancer.

Nappi RE, Cassani C, Rossi M, Zanellini F, Spinillo A.

Minerva Ginecol. 2016 Oct;68(5):602-12. Epub 2016 Feb 29. Review.

PMID:
26928421
20.

Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.

Tschernichovsky R, Goodman A.

Oncologist. 2017 Apr;22(4):450-459. doi: 10.1634/theoncologist.2016-0444. Epub 2017 Mar 17. Review.

PMID:
28314837

Supplemental Content

Support Center